Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
- Author:
Jaehyun LEE
1
;
Yong Jae SHIN
;
Kyoungmin LEE
;
Hee Jin CHO
;
Jason K SA
;
Sang Yun LEE
;
Seok Hyung KIM
;
Jeongwu LEE
;
Yeup YOON
;
Do Hyun NAM
Author Information
- Publication Type:Original Article
- Keywords: Glioblastoma; Semaphorin-3A; Neutralization; Fully human antibody
- MeSH: Antibodies; Brain; Brain Neoplasms; Cell Line; Cell Movement; Computational Biology; Dataset; Down-Regulation; Genome; Glioblastoma*; Glioma; Heterografts; Humans; Immunoglobulin G; In Vitro Techniques; Kinetics; Macrophages; Mass Screening; Methods; RNA, Messenger; Semaphorin-3A
- From:Cancer Research and Treatment 2018;50(3):1009-1022
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Glioblastoma (GBM) is classified as one of the most aggressive and lethal brain tumor. Great strides have been made in understanding the genomic and molecular underpinnings of GBM, which translated into development of new therapeutic approaches to combat such deadly disease. However, there are only few therapeutic agents that can effectively inhibit GBM invasion in a clinical framework. In an effort to address such challenges, we have generated anti-SEMA3A monoclonal antibody as a potential therapeutic antibody against GBM progression. MATERIALS AND METHODS: We employed public glioma datasets, Repository of Molecular Brain Neoplasia Data and The Cancer Genome Atlas, to analyze SEMA3A mRNA expression in human GBM specimens. We also evaluated for protein expression level of SEMA3A via tissue microarray (TMA) analysis. Cell migration and proliferation kinetics were assessed in various GBM patient-derived cells (PDCs) and U87-MG cell-line for SEMA3A antibody efficacy. GBM patient-derived xenograft (PDX) models were generated to evaluate tumor inhibitory effect of anti-SEMA3A antibody in vivo. RESULTS: By combining bioinformatics and TMA analysis, we discovered that SEMA3A is highly expressed in human GBM specimens compared to non-neoplastic tissues. We developed three different anti-SEMA3A antibodies, in fully human IgG form, through screening phage-displayed synthetic antibody library using a classical panning method. Neutralization of SEMA3A significantly reduced migration and proliferation capabilities of PDCs and U87-MG cell line in vitro. In PDX models, treatment with anti-SEMA3A antibody exhibited notable tumor inhibitory effect through down-regulation of cellular proliferative kinetics and tumor-associated macrophages recruitment. CONCLUSION: In present study, we demonstrated tumor inhibitory effect of SEMA3A antibody in GBM progression and present its potential relevance as a therapeutic agent in a clinical framework.
